Myeloid Neoplasm Post Cytotoxic Therapy

Myeloid Neoplasm Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

65 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 24.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04550442	Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	terminated	Phase 1 / Phase 2	34	M.D. Anderson Cancer CenterOTHER	1	Jun 5, 2026	clinicaltrials
NCT04160052	Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome	terminated	Phase 1 / Phase 2	51	M.D. Anderson Cancer CenterOTHER	1	Feb 12, 2026